The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to revised criteria for staging and of the International Working Group Guidelines of 2007 for response. As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomography (CT) was formally incorporated into standard staging for FDG-avid lymphomas. A modification of the Ann Arbor descriptive terminology will be used for ana...

/pdf/recommendations-for-initial-evaluation-staging-and-response-5zfzjttmb3.pdf

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.

https://www.unitypoint.org/desmoines/filesimages/Cancer%20Education/Oncology%20Nursing%20Conference/2015/2014%20NCCN%20Clin%20Pract%20Guidelines%20Male%20Sex%20Dysf.pdf

Clinical practice guidelines in oncology

The origin and evolution of mutations in acute myeloid leukemia.

Cardiac dysfunction resulting from exposure to cancer therapeutics
was first recognized in the 1960s, with the widespread introduction
of anthracyclines into the oncologic therapeutic armamentarium.
Heart failure (HF) associated with anthracyclines was then recognized
as an important side effect. As a result, physicians learned to limit their
doses to avoid cardiac dysfunction. Several strategies have been used
over the past decades to detect it. Two of them evolved over time
to be very useful: endomyocardial biopsies and monitoring of left ven-
tricular (LV) ejection fraction (LVEF) by cardiac imaging. Examination
of endomyocardial biopsies proved to be the most sensitive and spe-
cific parameter for the identification of anthracycline-induced LV
dysfunction and became the gold standard in the 1970s. However,
the interest in endomyocardial biopsy has diminished over time
because of the reduction in the cumulative dosages used to treat ma-
lignancies, the invasive nature of the procedure, and the remarkable
progress made in noninvasive cardiac imaging. The noninvasive
evaluation of LVEF has gained importance, and notwithstanding the
limitations of the techniques used for its calculation, has emerged as
the most widely used strategy for monitoring the changes in cardiac
function, both during and after the administration of potentially car-
diotoxic cancer treatment.

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

BACKGROUNDS This retrospective study evaluated treatment outcomes in patients undergoing autologous stem cell transplantation (ASCT) for relapsed/refractory Hodgkin lymphoma (HL). PATIENTS AND METHODS Overall, 194 HL patients treated with ASCT between 2000 and 2009 were analyzed. Survival was calculated using Kaplan-Meier method and differences in survival between subgroups with log-rank test. RESULTS Best responses observed after ASCT: 124 complete and 35 partial remissions, 2 patients with stable disease and 33 relapses/progressions. During a median follow-up of 44 months, seventy patients after ASCT progressed/relapsed. Thirty-seven patients received salvage chemotherapy only with or without radiotherapy, 25 underwent allogeneic stem cell transplantation (SCT), 4 the second ASCT and 4 refused treatment. 5-year overall survival after ASCT was 71% and progression-free survival 54%. Median survival of the 70 patients relapsing after ASCT was 16.9 months. Median survival in patients after allogeneic SCT was 31.8 months and 12.4 months in patients treated with other modalities (p = 0.21). Overall mortality was 26.3% (51/194 patients): 13.4% progressions/relapses of HL and 12.9% non-relapse mortality. CONCLUSION Efficacy of ASCT was confirmed in 54% progression-free survivors. Median survival after ASCT failure is relatively short. There is a slightly longer overall survival after allogeneic SCT, although not statistically significant when compared to other approaches.

[Treatment of patients with relapsed/refractory Hodgkin lymphoma].

The climatic data on which the current generation of the Eurocodes are based are mostly about 20 years old, with some exceptions of recent updates at a national level. The second generation of the Eurocodes for structural design is expected to be nationally implemented within next few years and operational National Annexes should be subsequently developed and the climatic maps revised. Some models for extreme climate actions are still missing within Eurocodes including wind action effects due to non-synoptic storms, which are common in most of the world and are of increasing importance in Europe.The aim of this contribution is to analyse how the impact of anticipated changes in European climate could affect the assessment of design weather parameters, including the partial factor design approach for structures according to Eurocodes, based on current knowledge concerning projectionmodels of future climate in Europe.

Implication of climate changes on design of structures

Číst, pochopit, interpretovat. Literární text ve výuce cizího jazyka a ve výuce literatury

Hodgkinův lymfom (HL) je vylecitelne nadorove onemocněni u 80 % až 90 % mladsich pacientů, ale prognoza starsich pacientů
nad 60 let je výrazně horsi. Starsi pacienti představuji 10–20 % ze vsech připadů HL. V důsledku horsiho celkoveho zdravotniho
stavu a dalsich přidružených onemocněni je jejich tolerance chemoterapie výrazně nižsi ve srovnani s mladsimi pacienty s nutnosti
redukce davek chemoterapie. Na zakladě literarnich udajů a dat z ceskeho registru HL jsou v clanku shrnuty doporuceni lecby,
možna toxicita a prognoza pacientů v seniorskem věku. V soucasnosti se i u starsich pacientů zkousi nove leky samostatně nebo
v kombinaci s chemoterapii s cilem zvýsit ucinnost a omezit nežadouci ucinky lecby.

/pdf/hodgkinuv-lymfom-seniorskeho-veku-aypm8d99tp.pdf

Hodgkinův lymfom seniorského věku

Background: PET2-adapted approach after 2 cycles of ABVD reduced treatment intensity in the majority of patients with early stages of classical Hodgkin lymphoma (cHL) according to EORTC H10 trial. GHSG HD17 enabled omission of radiotherapy in PET4-negative early unfavorable HL treated with 2 cycles of BEACOPP escalated and 2 cycles of ABVD (2 + 2 chemotherapy). We compared PET2-adapted approach with 2 + 2 chemotherapy followed by 30 Gy of involved-node radiotherapy (INRT) regardless of interim PET in patients with early unfavorable cHL assessed according to the GHSG risk factors. Methods: Overall, 224 patients with early unfavorable cHL (aged 18–60 years) prospectively observed in the Czech Hodgkin Lymphoma Study Group Registry between 2003–2021 were analyzed. Patients in clinical stage IIB with massive mediastinal tumor and/or with extranodal disease were excluded. Overall, 194 patients received 2 + 2+INRT chemotherapy and 30 patients were treated with PET2-adapted approach: 29 PET2-negative patients received 4 cycles of ABVD and 30 Gy of INRT and one PET2-positive patient was treated with 2 cycles of ABVD plus 2 cycles of BEACOPP escalated and 30 Gy INRT. Results: Median age at the time of cHL diagnosis was 32 (range 18–59) years. Median follow-up was longer in the 2 + 2+INRT group (98.9, range 6.2–211.7) months compared to the PET2-adapted approach (30.8, range 9.8–90.4) months. The 2-year progression-free survival and 2-year overall survival did not differ between two groups (99.5% [95% CI 98.5%–100%]) and 100% [95% CI 100%–100%]), respectively. The rate of patients with neutropenia grade 3 and anemia grade 3 did not differ significantly between both groups (p=0.09 and p=0.60, respectively). Thrombocytopenia was more frequent in the 2 + 2+INRT group (p0.001). Grade 3 non-hematological toxicity occurred in 3 patients in the 2 + 2+INRT group (2 infections, 1 deep vein thrombosis). Conclusion: This retrospective analysis indicates that there is no superiority in progression-free survival and overall survival when comparing 2 + 2 chemotherapy and INRT to PET2-adapted approach. The toxicity is higher in the 2 + 2+INRT group. This work was supported by the following grants AZV NU22-03–00182 from the Ministry of Health of the Czech Republic and Cooperatio Program awarded by the Charles University in Prague in the Czech Republic. 

https://doi.org/10.1097/01.hs9.0000890660.81038.b1

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma

Jana Markova

Papers

[Treatment of patients with relapsed/refractory Hodgkin lymphoma].

Implication of climate changes on design of structures

Číst, pochopit, interpretovat. Literární text ve výuce cizího jazyka a ve výuce literatury

Hodgkinův lymfom seniorského věku

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma